Connect Biopharma's Rademikibart Phase 2 Asthma/COPD Trials Progress as Planned After Positive Interim Review
Summary
Connect Biopharma announced that an independent Data Monitoring Committee completed its interim review of Phase 2 trials for rademikibart in asthma and COPD, recommending no changes to sample size, indicating positive trial progression and safety.
Key Events
-
Phase 2 Rademikibart Trials Progress
The independent Data Monitoring Committee (DMC) completed its pre-specified interim analysis of efficacy for the Phase 2 Seabreeze STAT asthma and COPD trials evaluating rademikibart.
-
No Sample Size Change Recommended
The DMC recommended no change in sample size, indicating that enrollment will continue as planned, which is a positive signal for trial progression.
-
Positive Safety Profile Noted
Rademikibart continues to be well tolerated in the studies, with no treatment-related serious adverse events or discontinuations due to adverse events reported to date.
-
Topline Data Expected Mid-2026
The company remains on track to report topline results from both Seabreeze STAT studies in mid-2026, with plans to engage the FDA for a Phase 3 program.
Analysis
This 8-K reports a crucial interim milestone for Connect Biopharma's lead asset, rademikibart. The Data Monitoring Committee's decision to continue the Phase 2 Seabreeze STAT trials for asthma and COPD without recommending changes to the sample size is a positive signal, suggesting no significant safety concerns or lack of efficacy were identified at this stage. For a clinical-stage biopharmaceutical company, successful progression through trials is paramount, especially given the company's recent financial performance. This update de-risks the program somewhat and maintains the timeline for topline data in mid-2026, which will be a significant catalyst for the stock.
At the time of this filing, CNTB was trading at $2.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $147M. The 52-week trading range was $0.65 to $3.82. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.